INTRODUCTION
Amyotrophic lateral sclerosis (ALS) and spinal bulbar muscular atrophy (SBMA, also known as Kennedy's disease) are two major motor neuron diseases. ALS is a rapidly progressive and fatal disorder characterised by relentless impairment of motor function following the degeneration of the upper and lower motor neurons (UMN, LMN) 1 . In SBMA LMN degeneration, caused by an expanded cytosine-adenine-guanine (CAG) repeat in the first exon of the androgen receptor (AR) gene 2 , induces progressive disabling bulbar and limb weakness at a slower rate 3 . At disease onset, ALS and SBMA may show similar symptoms, and distinguishing the two disorders is of paramount interest 4 .
There are still no effective disease-modifying therapies for either ALS or SBMA, and, whilst promising targets for prospective therapeutics have been identified 5 , a serious limitation for clinical trials is the shortage of sensitive and reliable outcome measures for assessing disease progression 6 .
Skeletal muscle MRI can sensitively detect muscle involvement in neuromuscular diseases 7, 8 , and differentiate distinct pathological features, such as muscular fat infiltration or intra-muscular edema 9 associated with acute denervation 10 . Muscle MRI demonstrated promise as a biomarker of disease progression in both myopathies and neuropathies 11 .
In this study we investigated muscle MRI in SBMA and ALS by studying the lower limb and the head-neck regions, which are characteristically affected in both disorders. We report that muscle MRI can differentiate between both diseases. Moreover, we show that quantitative muscle MRI measures correlate with the clinical severity of disease, thus supporting their validity as outcome measures for quantifying disease progression in clinical trials.
METHODS

Study Design and patient recruitment
We performed a prospective cross-sectional study, assessing muscular MRI of the head-neck region and lower limbs in 21 male adult consecutive patients with SBMA, and 21 male and female consecutive patients with ALS who were attending the national Kennedy`s disease clinic and motor neuron disease clinic at the National Hospital for Neurology and Neurosurgery, Queen Square, London, UK between 2015 and 2017.
Patients with genetically confirmed mutation of androgen receptor (AR) gene were included in the SBMA group. Patients eligible for the ALS group all presented with a history of at least clinically possible disease according to revised El Escorial criteria 12 .
Additionally, 16 healthy subjects comparable to the patient groups concerning their demographic data were recruited as a control group. Differences in gender prevalence in the ALS-and SBMA-groups were taken into account, where for comparisons with ALS patients both female and male healthy volunteers were considered, whereas SBMA patients were compared to male control subjects only. General exclusion criteria for all participants were concomitant neuromuscular diseases and safety-related MRI contraindications.
Data from one ALS patient and one SBMA patient were excluded from any further analysis due to incomplete scan examination. After MRI examinations were completed, in the SBMA-group data from three patients had to be excluded due to insufficient image quality in the head-neck region. Two patients' data were excluded for the same reason from the ALS-group. Additionally, in one control subject head-neck imaging could not be acquired due to the inability to tolerate lying still in the MR-scanner for the required examination time. The study was approved by the local ethics committee and all participants provided written informed consent at enrolment.
Data acquisition
Clinical and functional testing
All participants were functionally rated using the ALS Functional Rating Scale-Revised (ALSFRS-R) 13 . In SBMA patients, functional state was additionally scored according to the SBMA Functional Rating Scale (SBMA-FRS) 14 and supplementary measurements with the recently introduced adult myopathy assessment tool (AMAT) were performed 15 . All participants underwent detailed assessment including medical history and an examination of the clinical and neurological status.
MRI Imaging
MRI was performed on a clinical 3 T scanner (MAGNETOM Skyra, Siemens, Erlangen, Germany). A 20-channel head-neck matrix coil was used for imaging of the head-neck region. T1w-imaging was performed in the sagittal plane encompassing the oral cavity using a 3D isotropic fast spin-echo technique with slab selective, variable flip angle refocussing pulses (T1w-SPACE, TR = 700 ms,TE = 11.0 ms,NSA = 1, iPat = 2, ) were used to enable calculation of water-and fat-only images 16 . Total scan time for 3-point Dixon measurement was 7:54 minutes.
After this, imaging of the lower extremities was performed using the Siemens multi-channel lower-limb ('PA matrix') coil. Transverse 2D T1w turbo spin-echo (TSE) imaging (TR = 695 ms, TE = 9.4 ms, NSA = 1, 51 slices, gap = 3 mm, FOV = 420 mm, voxel size = 0.8 × 0.8 × 3 mm) was performed separately at the level of the mid-thigh and mid-calf, to include both limbs. Furthermore, transverse short tau inversion recovery (STIR) acquisitions (TR = 5200 ms, TE = 39 ms, TI = 220 ms, NSA = 1, iPAT = 2, 31 slices, FOV = 420 mm, voxel size = 1.1 × 1.1 × 6.0 mm, slice gap = 6 mm) were performed separately at the level of the mid-thigh and mid-calf to include both limbs. Finally, transversal T1w-gradient echo 3-point Dixon sequences comparable to the head-neck region (TR = 102.0 ms, TE = 3.45/ 4.6/ 5.75 ms, NSA = 4, 9 slices, FOV = 420 mm, voxel size = 1.3 × 1.3 × 6 mm, slice gap = 12 mm) were performed, with scan geometry adapted to the lower extremities' regions. Total scan time for all sequences at the lower limbs was about 22 minutes.
MRI Data Analysis
Semi-quantitative Muscle MRI Analysis
Semi-quantitative data analysis was based on T1w and STIR muscle imaging. Muscle fat infiltration in the thigh and calf region was assessed visually on T1w-MRI using the six-point scale (0 = normal, 1 = mild fatty streaks, 2a = early confluence, 2b = fatty infiltration 30-60%, 3 = fatty infiltration >60%, 4 = complete fat replacement) as described by Mercuri et al.
17
. Presence of T2w hyper-intensities at thigh and calf level were assessed visually on STIR-MRI sequences and rated by a three-point scale (0=none, 1=mild, 2=marked) as proposed by Morrow et al. 18 . Muscles were identified and assessed on both sides. All images were assessed and rated in consensus by two readers (U.K., K.T.) blinded to clinical diagnosis, after appropriate training.
In the head-neck region the following bulbar muscles were rated on the Mercuri scale: mastication muscles 
Quantitative Muscle MRI Analysis
Following the semi-quantitative MRI analysis, a single observer (U.K.) blinded to subject groups defined regions of interest (ROIs) on images showing the lower limb and tongue muscles derived from the respective unprocessed shortest TE-Dixon acquisition (TE = 3.45 ms) in all subjects using the ITK-SNAP software 19 . A representative single mid-volume slice showing the previously semi-quantitatively assessed muscle groups was selected for placing the ROIs. Selection of inter-subject comparable slices was assured by identification of specific anatomical landmarks in the lower limb-(lateral tibial condyle) and the head-neck region (pituitary infundibulum). Concerning the tongue, intrinsic muscles (IM) and extrinsic muscles (GG and GH) were differentiated. After performing fat-water separation according to the method of Glover and Schneider
16
, fat fraction maps were obtained by calculating for each pixel
where S f and S w are the respective signal intensities from the same pixel location in the separated water and fat images. Muscle specific fat fraction (FF msc ) was then obtained for each muscle and muscle compartment by overlaying the manually defined individual ROIs upon the inherently co-registered fat fraction maps 11 and calculating the mean FF value and cross-sectional area (CSA) for each ROI.
Besides the muscle specific fat fraction (FF msc ) for each muscle the overall muscle fat fraction percentage (FF all ) was calculated, representing a summary measure as the mean of individual muscle values weighted by total number of voxels:
with i: 1=left, 2= right; m = total number of muscle ROIs at each level
In equation 2 n ij denotes the number of voxels in a certain muscle specific ROI of the left or right side, where index j relates to a respective muscle on each side. Analogously, the MRI-based functional remaining muscle area (fRMA msc ), defined as the CSA of the muscle tissue not replaced by fat, was computed as:
Statistical Analysis
Statistical analyses were performed with SPSS version 22 (Armonk, NY) with an alpha level of 0.05. As appropriate to the distribution of data, measures are reported as mean ± SD respectively median and interquartile range (IQR). For inter-group comparisons, Kruskal-Wallis-tests, 2-sample t-tests and MannWhitney-U-tests were applied as appropriate. Missing data were excluded from analyses. Correlations of MRI data with clinical measures were investigated with Spearman (rho) or Pearson coefficients as appropriate for the distribution of data.
RESULTS
Participant demographics and clinical findings
The study included two patient groups, SBMA (N = 21) and ALS (N = 21), along with healthy controls (N = 16). For analysis exclusion criteria we refer to the methods section. Mean age was 50.7 (SD 17) years and 54.4 (SD 14.6; p = 0.53) years in the SBMA and SBMA-control group respectively ( Table 1) Figure 1C ). The muscle specific fat fraction (FF msc ) confirmed the pattern identified in the semi-quantitative assessments: in SBMA patients, the highest FF msc was observed in the posterior TMC (biceps femoris posterior (BFP), followed by semitendinosus (ST) and SM) and in the anterior TMC (VL, followed by vastus intermedius (VI) and rectus femoris (RF)); the medial TMC was relatively spared with the lowest FF msc in SBMA patients ( Figure 1C) . Despite a significantly higher overall FF all compared to their matched controls, no specific pattern of fat infiltration was observed on single muscle analysis in ALS patients. However, there was significant atrophy of thigh muscles in ALS patients compared to controls (Table 1) .
In summary, widespread intramuscular fat accumulation was observed in SBMA patients occurring with a preferential involvement of muscles in the anterior and posterior TMC. Compared to controls, significant atrophy of calf muscles in ALS patients was observed ( Table 1) .
In summary, widespread intramuscular fat accumulation, occurring with a specific pattern relatively sparing the TA and TP muscles and more severely affecting the posterior compartment muscles, was observed in the SBMA patients. ALS also showed changes, albeit at lesser levels, and with a different pattern, the lateral compartment being the most affected.
Fat suppressed STIR images show significant changes in both SBMA and ALS
As the rapid course of ALS may contribute to the modest level of fat infiltration in this condition, we investigated whether semi-quantitative fat suppressed STIR sequences would reveal more identifiable changes deriving from quickly developing muscle denervation. Marked STIR hyperintensities were observed in almost all TMC and CMC in both patient groups compared to their age-matched controls.
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Using the rating scale proposed by Morrow et al. 18 , marked muscle tissue hyperintensities (Morrow grade 2) were detected in the anterior and posterior TMC of SBMA patients ( Figure 3A) ; in the calves of SBMA patients, STIR abnormalities were observed in all muscle compartments ( Figure 3C ). In the ALS patient group, the anterior TMC was the most altered, albeit signal abnormalities were detected in every CMC. In healthy controls, no marked hyperintensities were observed in any of the TCM, whilst in the calf, we noticed STIR signal hyperintensities of MG, previously described as "central stripe" 10 , which corresponds to the muscle end-plate region of this muscle (Figure 3C, 3D) .
In summary, differently from T1w sequences, STIR sequences detect changes in both conditions, with alterations in the calves being more marked in ALS.
Muscle MRI detects widespread muscle changes at bulbar level in SBMA
Although bulbar muscles are affected in both SBMA and ALS, these have rarely been included in previous muscle MRI studies 20, 21 . We therefore assessed fatty changes of bulbar muscles using both T1w and 3-point Dixon sequences.
T1w imaging showed a moderate to severe involvement (Mercuri grade 2b -4) of mastication and swallowing muscles in SBMA, whilst in contrast, ALS patients showed predominantly only mild to moderate muscle fat infiltration of these muscle groups (Mercuri grade 1 -2b; Figure 4A ). Both patient groups showed moderate to severe involvement (Mercuri 2b or higher) of intrinsic and extrinsic tongue muscles, including the genioglossus (GG), geniohyoideus (GH), hyoglossus (HG) and mylohyoideus (MH). Notably, 12.5% of healthy subjects also showed moderate muscle fat infiltration (Mercuri grade 2b) in extrinsic tongue muscles ( Figure 4A ). Quantitative FF all were significantly higher in SBMA patients (median 21.69%, IQR 16.66%), compared to their matched controls (median 6.63, IQR 3.50; M-W-U = 18; p < 0.001; Figure 4B ). FF msc were highest in the intrinsic tongue muscles, followed by extrinsic tongue muscles GG (median 16.56%, IQR 16%) and GH (median 10.29%, IQR 15%) in SBMA patients. No significant difference in FF all was seen between ALS patients (median 8.68%, IQR 5.74%) and their matched controls (median 6.76%, IQR 2.84%; M-W-U = 94; p = 0.15; Figure 4B ).
In summary, fat infiltration in bulbar muscles is able to differentiate SBMA from both ALS and controls.
Muscle MRI correlates with functional rating scales in MND
In order to test whether the MRI findings reflected disease severity, we calculated correlations between muscle MRI measures and functional measures, using established clinical rating instruments for each condition: the ALSFRS-R for ALS patients and the SBMA-FRS and the AMAT score for SBMA.
We initially asked whether the overall mean FF all of combined thigh and calf level correlated with the LL subscale from ALSFRS-R and found there was a strong negative correlation between FF all and disability in SBMA patients (ρ = -0.86, p < 0.001) and a significant negative correlation also in ALS patients (ρ = -0.47, p = 0.04; Figure 5A ). In SBMA, the FF all strongly negatively correlated with the total AMAT score (ρ = -0.77, p < 0.001. Figure 5C ). It is important to note that FF all did not correlate with age in healthy controls (ρ = -0.06, p = 0.8).
Since our results show that fat infiltration is not a prominent feature in ALS, whilst active denervation changes are occurring, we next asked whether assessment of the functional remaining muscle area (fRMA msc ) would take muscle atrophy into account and provide a better measure for ALS. Indeed, in ALS patients the fRMA msc correlated strongly with ALSFRS-R LL subscales (ρ = 0.68, p = 0.002; Figure 5B ). The combined thigh and calf level fRMA msc of SBMA patients also correlated strongly with SBMA-FRS LL subscales (ρ = 0.70, p = 0.003), and with the AMAT score (r = 0.58, p = 0.009, Figure 5C ).
In summary, MRI measures correlate with functional measures in both SBMA and ALS, supporting their exploration as quantitative biomarkers of disease progression.
DISCUSSION
In the present study, we performed skeletal muscle MRI imaging on cohorts of two major forms of adult motor neuron disease, ALS and SBMA. Furthermore, for the first time, we also extended quantitative fat fraction quantitation protocols to the head and neck region, given the involvement of bulbar muscles in these diseases. .
In accord with these findings, we observed marked STIR hyperintensities in all thigh and calf muscles in both SBMA and ALS patients, highlighting the potential of fat-suppressed MRI sequences to reveal changes deriving from muscle denervation in the rapid course of disease progression in ALS. . SBMA is slowly progressive and rare, and more reliable, quantitative outcome measures would both reduce the duration as well as the size, and cost, of clinical trials. Survival has often been used in ALS trials 33 , but novel sensitive outcome measures in ALS would also enable shorter trials to be undertaken, reducing costs and allowing more therapies to be tested. Muscle MRI appears to fulfil the criteria for such a biomarker, due to its reproducibility, its capability of generating quantitative measurements 1 4 and its observer independence 34 . Furthermore, fat infiltration or denervation-related changes detected by muscle MRI may provide the ground for the development of neurochemical markers, which reflect these changes. However, further studies will be necessary to assess the sensitivity of muscle MRI to detect progressive changes in these diseases and to determine the full potential of muscle MRI as a reliable outcome measure for ALS and SBMA. Significant correlations were observed between fRMA of LL and AMAT score in SBMA patients (right, r = 0.58, p = 0.009). LL, lower limbs; AMAT, adult myopathy assessment tool; ALSFRS-R, ALS functional rating scale -revised; FF all , overall muscle fat fraction percentage; fRMA, functional remaining muscle area.
